Prima BioMed Ltd (IMMP) – What Are Analysts Thinking About This Stock?

Shares of Prima BioMed Ltd (NASDAQ:IMMP) have earned a consensus rating of “Hold” from the five research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $110.00.

IMMP has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Prima BioMed in a report on Tuesday, October 6th. Jefferies Financial Group upgraded Prima BioMed from a “hold” rating to a “strong-buy” rating in a report on Monday, September 14th.

Prima BioMed Price Performance

Prima BioMed stock opened at $3.46 on Friday. The company’s 50 day simple moving average is $4.64 and its 200 day simple moving average is $15.52. Prima BioMed has a fifty-two week low of $2.66 and a fifty-two week high of $70.60.

Prima BioMed (NASDAQ:IMMP) last issued its earnings results on Thursday, July 30th. The biotechnology company reported ($1.80) EPS for the quarter. The business had revenue of $3.68 million for the quarter.

About Prima BioMed

Prima BioMed Limited was an Australian biotechnology company focused on developing immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the body’s immune response against tumors. Its principal product candidate was IMP321, also known as eftilagimod alpha, a soluble LAG-3 protein intended to stimulate antigen-presenting cells and support T-cell activity. Prima BioMed evaluated the therapy in combination with other cancer treatments, including chemotherapy and immune checkpoint inhibitors, across several solid-tumor indications.